Litcius/Paper detail

A randomized, double-blind, placebo controlled, phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of LB-102, a selective dopamine D2/3/5-HT7 inhibitor

Lukasz Biernat, V. Grattan, Mark S. Hixon, Zachary Prensky, Andrew R. Vaino

2022Psychopharmacology11 citationsDOI

Topics & Concepts

PharmacokineticsTolerabilityDosingMedicinePharmacodynamicsPharmacologyPlaceboAdverse effectCmaxAnesthesiaDystoniaAmisulprideInternal medicineAntipsychoticSchizophrenia (object-oriented programming)PathologyPsychiatryAlternative medicineSchizophrenia research and treatmentNeurotransmitter Receptor Influence on BehaviorReceptor Mechanisms and Signaling
A randomized, double-blind, placebo controlled, phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of LB-102, a selective dopamine D2/3/5-HT7 inhibitor | Litcius